A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, non-controlled, single-arm clinical trial to evaluate the
safety, efficacy and population pharmacokinetics of Amphotericin B cholesteryl Sulfate
Complex for Injection domestic formulations (ABCD) in the treatment of confirmed invasive
candidiasis (IC) and confirmed/clinically diagnosed invasive aspergillus (IA) disease.
Phase:
Phase 3
Details
Lead Sponsor:
CSPC Ouyi Pharmaceutical Co., Ltd.
Treatments:
Amphotericin B Cholesteryl sulfate Liposomal amphotericin B